Compare Walt Disney Co (DIS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs IDEXX Laboratories, Inc. — how do they compare? Walt Disney Co trades at $107.7 (market cap $184.79B), while IDEXX Laboratories, Inc. trades at $519.96 (market cap $40.43B). The key difference: Walt Disney Co is far larger — about 4.6× IDEXX Laboratories, Inc.'s market cap, and Walt Disney Co pays a 1.4% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DIS | IDXX | |
|---|---|---|
Market Cap | $184.79B | $40.43B |
Volume | 13,033,550 | 692,164 |
Sector | Media | Health |
52-Week High | $116.65 | $766.68 |
52-Week Low | $92.40 | $504.70 |
Typical Hold Time | 199 Days | 46 Days |
Enterprise Value | $225.65B | $41.32B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $104.76, up 0.7% with a bullish technical signal supported by moving averages. The company shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth reaching $94.43 billion in 2025. Disney's net income margin expanded significantly to 13.13% while maintaining a reasonable P/E ratio of 22.07. Recent news highlights the company's $60 billion parks investment and streaming margin improvements above 13%.
Disney presents a compelling investment case with analyst consensus pointing to 20% upside to the $125.67 price target. The company's diversified entertainment ecosystem and accelerating DTC profitability support growth, though risks include free cash flow pressure from elevated investments and competitive streaming landscape. Institutional sentiment remains positive with 62.5% buy ratings among 64 analysts covering the stock.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
